
12th Annual Meeting of Korean Society of Medical Oncology & **2019 International Conference**





PERSONAL INFORMATION.		
Title	■ Prof. □ Dr. □ Others ()	
Academic Degree	□ M.D. □ RN ■ PhD. □ Others ()	
Gender	☐ Mr. ■ Ms.	
Name	Yeon Hee Park	
Organization	Samsung Medical Center	
Department	Hematology-Oncology	
Position	Professor	
Country	Korea	

1 03101011		110103301		
Country		Korea		
CURRICULUM VITAE				
Educational Background	1993 2001 2006 2007	M.D. Ewha Woman's University Medical School Ph.D. Kyunghee University Postdoc fellow UCSD Cancer Center, San Diego, USA Postdoc fellow Sydney Kimmel Cancer Center, San Diego, USA		
Work Experience		 Staff Physician, Medical Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea Associate Professor, Hematology-Oncology, Samsung Medical Center, 		
	2014 prese 2017	Sungkyunkwan University School of Medicine, Seoul, Korea Professor, Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Director, Breast Cancer Center, Samsung Medical Center		
Publications Featuring Your Research Findings within Last 5 Years	moled Park vertical Park positive giment observed expenses outcome of the control	Park YH, et al. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nat Commun. 2018 Apr 30;9(1):1725 Park YH, et al. Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer Oncoimmunology. 2018 May 24;7(8):e1466768 Park YH, et al. A phase II trial of the pan-HER inhibitor poziotinib, inpatients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial Int J Cancer. 2018 Dec 15;143(12):3240-3247 Park YH, et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol, 2013 Park YH, et al. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. Eur J Cancer, 2014 Park YH, et al. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment. Br J Cancer, 2014		